https://www.repository.cam.ac.uk/items/a5681635-caf9-45ec-b895-52bee4b04bd5
Two-year treatment experience with BI 655064, an antagonistic anti-CD40 antibody, in patients with...
ObjectiveTo evaluate the long-term efficacy and safety of different doses of BI 655064 versus placebo added to standard of care during maintenance treatment...